Abstract
Escherichia coli has a complex and versatile nature and continuously evolves from non-virulent isolates to highly pathogenic strains causing severe diseases and outbreaks. Broadly protective vaccines against pathogenic E. coli are not available and the rising in both, multi-drug resistant and hypervirulent isolates, raise concern for healthcare and require continuous efforts in epidemiologic surveillance and disease monitoring. The evolving knowledge on E. coli pathogenesis mechanisms and on the mediated immune response following infection or vaccination, together with advances in the “omics” technologies, is opening new perspectives toward the design and development of effective and innovative E. coli vaccines.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahmed B, Loos M, Vanrompay D, Cox E (2013a) Mucosal priming of the murine immune system against enterohemorrhagic Escherichia coli O157:H7 using Lactococcus lactis expressing the type III secretion system protein EspB. Vet Immunol Immunopathol 152(1–2):141–145
Ahmed S, Byrd W, Kumar S, Boedeker EC (2013b) A directed intimin insertion mutant of a rabbit enteropathogenic Escherichia coli (REPEC) is attenuated, immunogenic and elicits serogroup specific protection. Vet Immunol Immunopathol 152(1–2):146–155
Ahmed T, Bhuiyan TR, Zaman K, Sinclair D, Qadri F (2013c) Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea. Cochrane Database Syst Rev (7):CD009029
Alerasol M, Mousavi Gargari SL, Nazarian S, Bagheri S (2014) Immunogenicity of a fusion protein comprising coli surface antigen 3 and labile B subunit of enterotoxigenic Escherichia coli. Iran Biomed J 18(4):212–218
Alteri CJ, Hagan EC, Sivick KE, Smith SN, Mobley HL (2009) Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog 5(9):e1000586
Amos GC, Hawkey PM, Gaze WH, Wellington EM (2014) Waste water effluent contributes to the dissemination of CTX-M-15 in the natural environment. J Antimicrob Chemother 69(7):1785–1791
Asadi Karam MR, Rezaei AA, Siadat SD, Habibi M, Bouzari S (2017) Evaluation of prevalence, homology and immunogenicity of dispersin among enteroaggregative Escherichia coli isolates from Iran. Iran Biomed J 21(1):40–47
Asper DJ, Karmali MA, Townsend H, Rogan D, Potter AA (2011) Serological response of Shiga toxin-producing Escherichia coli type III secreted proteins in sera from vaccinated rabbits, naturally infected cattle, and humans. Clin Vaccine Immunol 18(7):1052–1057
Baldi DL, Higginson EE, Hocking DM, Praszkier J, Cavaliere R, James CE, Bennett-Wood V, Azzopardi KI, Turnbull L, Lithgow T, Robins-Browne RM, Whitchurch CB, Tauschek M (2012) The type II secretion system and its ubiquitous lipoprotein substrate, SslE, are required for biofilm formation and virulence of enteropathogenic Escherichia coli. Infect Immun 80(6):2042–2052
Barry EM, Wang J, Wu T, Davis T, Levine MM (2006) Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Vaccine 24(18):3727–3734
Basu S (2015) Neonatal sepsis: the gut connection. Eur J Clin Microbiol Infect Dis 34(2):215–222
Bauer HW, Alloussi S, Egger G, Blumlein HM, Cozma G, Schulman CC, Multicenter UTISG (2005) A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol 47(4):542–548 (discussion 548)
Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS (2002) Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents 19(6):451–456
Behrens RH, Cramer JP, Jelinek T, Shaw H, von Sonnenburg F, Wilbraham D, Weinke T, Bell DJ, Asturias E, Pauwells HL, Maxwell R, Paredes-Paredes M, Glenn GM, Dewasthaly S, Stablein DM, Jiang ZD, DuPont HL (2014) Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. Lancet Infect Dis 14(3):197–204
Blaak H, Hamidjaja RA, van Hoek AH, de Heer L, de Roda Husman AM, Schets FM (2014) Detection of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli on flies at poultry farms. Appl Environ Microbiol 80(1):239–246
Brumbaugh AR, Mobley HL (2012) Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vaccines 11(6):663–676
Brzuszkiewicz E, Gottschalk G, Ron E, Hacker J, Dobrindt U (2009) Adaptation of pathogenic E. coli to various niches: genome flexibility is the key. Genome Dyn 6:110–125
Brzuszkiewicz E, Thurmer A, Schuldes J, Leimbach A, Liesegang H, Meyer FD, Boelter J, Petersen H, Gottschalk G, Daniel R (2011) Genome sequence analyses of two isolates from the recent Escherichia coli outbreak in Germany reveal the emergence of a new pathotype: Entero-aggregative-haemorrhagic Escherichia coli (EAHEC). Arch Microbiol 193(12):883–891
Cai K, Gao X, Li T, Wang Q, Hou X, Tu W, Xiao L, Tian M, Liu Y, Wang H (2011) Enhanced immunogenicity of a novel Stx2Am-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine 29(5):946–952
Carl MA, Ndao IM, Springman AC, Manning SD, Johnson JR, Johnston BD, Burnham CA, Weinstock ES, Weinstock GM, Wylie TN, Mitreva M, Abubucker S, Zhou Y, Stevens HJ, Hall-Moore C, Julian S, Shaikh N, Warner BB, Tarr PI (2014) Sepsis from the gut: the enteric habitat of bacteria that cause late-onset neonatal bloodstream infections. Clin Infect Dis 58(9):1211–1218
Chakraborty S, Harro C, DeNearing B, Ram M, Feller A, Cage A, Bauers N, Bourgeois AL, Walker R, Sack DA (2015) Characterization of mucosal immune responses to enterotoxigenic Escherichia coli vaccine antigens in a human challenge model: response profiles after primary infection and homologous rechallenge with strain H10407. Clin Vaccine Immunol 23(1):55–64
Chen Q, Savarino SJ, Venkatesan MM (2006) Subtractive hybridization and optical mapping of the enterotoxigenic Escherichia coli H10407 chromosome: isolation of unique sequences and demonstration of significant similarity to the chromosome of E. coli K-12. Microbiology 152(Pt 4):1041–1054
Chui H, Chan M, Hernandez D, Chong P, McCorrister S, Robinson A, Walker M, Peterson LA, Ratnam S, Haldane DJ, Bekal S, Wylie J, Chui L, Westmacott G, Xu B, Drebot M, Nadon C, Knox JD, Wang G, Cheng K (2015) Rapid, sensitive, and specific Escherichia coli H antigen typing by matrix-assisted laser desorption ionization-time of flight-based peptide mass fingerprinting. J Clin Microbiol 53(8):2480–2485
Cohen D, Orr N, Haim M, Ashkenazi S, Robin G, Green MS, Ephros M, Sela T, Slepon R, Ashkenazi I, Taylor DN, Svennerholm AM, Eldad A, Shemer J (2000) Safety and immunogenicity of two different lots of the oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine in Israeli young adults. Infect Immun 68(8):4492–4497
Cross AS (1994) Antiendotoxin antibodies: a dead end? Ann Intern Med 121(1):58–60
Cross A, Artenstein A, Que J, Fredeking T, Furer E, Sadoff JC, Cryz SJ Jr (1994) Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. J Infect Dis 170(4):834–840
Cryz SJ Jr, Cross AS, Sadoff JC, Wegmann A, Que JU, Furer E (1991) Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans. J Infect Dis 163(5):1040–1045
Czerkinsky C, Holmgren J (2010) Topical immunization strategies. Mucosal Immunol 3(6):545–555
Darsley MJ, Chakraborty S, DeNearing B, Sack DA, Feller A, Buchwaldt C, Bourgeois AL, Walker R, Harro CD (2012) The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease. Clin Vaccine Immunol 19(12):1921–1931
Das JK, Tripathi A, Ali A, Hassan A, Dojosoeandy C, Bhutta ZA (2013) Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus. BMC Publ Health 13(Suppl 3):S11
Donnenberg MS, Finlay BB (2013) Combating enteropathogenic Escherichia coli (EPEC) infections: the way forward. Trends Microbiol 21(7):317–319
Dubreuil JD, Isaacson RE, Schifferli DM (2016) Animal enterotoxigenic Escherichia coli. EcoSal Plus 7(1)
Durant L, Metais A, Soulama-Mouze C, Genevard JM, Nassif X, Escaich S (2007) Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli. Infect Immun 75(4):1916–1925
Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA (2005) Diversity of the human intestinal microbial flora. Science 308(5728):1635–1638
Frank C, Faber MS, Askar M, Bernard H, Fruth A, Gilsdorf A, Hohle M, Karch H, Krause G, Prager R, Spode A, Stark K, Werber D, H. U. S. i. team (2011) Large and ongoing outbreak of haemolytic uraemic syndrome, Germany, May 2011. Euro Surveill 16(21)
Franz E, Veenman C, van Hoek AH, de Roda Husman A, Blaak H (2015) Pathogenic Escherichia coli producing Extended-Spectrum beta-Lactamases isolated from surface water and wastewater. Sci Rep 5:14372
Fratamico PM, DebRoy C, Liu Y, Needleman DS, Baranzoni GM, Feng P (2016) Advances in molecular serotyping and subtyping of Escherichia coli. Front Microbiol 7:644
Frey C, Obolensky W, Wyss H (1986) Treatment of recurrent urinary tract infections: efficacy of an orally administered biological response modifier. Urol Int 41(6):444–446
Gao X, Cai K, Shi J, Liu H, Hou X, Tu W, Xiao L, Wang Q, Wang H (2009) Immunogenicity of a novel Stx2B-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine 27(14):2070–2076
Gensollen T, Iyer SS, Kasper DL, Blumberg RS (2016) How colonization by microbiota in early life shapes the immune system. Science 352(6285):539–544
Geue L, Monecke S, Engelmann I, Braun S, Slickers P, Ehricht R (2014) Rapid microarray-based DNA genoserotyping of Escherichia coli. Microbiol Immunol 58(2):77–86
Giddings SL, Stevens AM, Leung DT (2016) Traveler’s diarrhea. Med Clin North Am 100(2):317–330
Giuliani MM, Del Giudice G, Giannelli V, Dougan G, Douce G, Rappuoli R, Pizza M (1998) Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 187(7):1123–1132
Gohar A, Abdeltawab NF, Fahmy A, Amin MA (2016) Development of safe, effective and immunogenic vaccine candidate for diarrheagenic Escherichia coli main pathotypes in a mouse model. BMC Res Notes 9:80
Gould LH, Mody RK, Ong KL, Clogher P, Cronquist AB, Garman KN, Lathrop S, Medus C, Spina NL, Webb TH, White PL, Wymore K, Gierke RE, Mahon BE, Griffin PM, G. Emerging Infections Program Foodnet Working (2013) Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000–2010: epidemiologic features and comparison with E. coli O157 infections. Foodborne Pathog Dis 10(5):453–460
Habibi M, Asadi Karam MR, Bouzari S (2016) Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis. APMIS 124(6):444–452
Hays MP, Ericsson AC, Yang Y, Hardwidge PR (2016) Vaccinating with conserved Escherichia coli antigens does not alter the mouse intestinal microbiome. BMC Res Notes 9(1):401
He Y, Xiang Z, Mobley HL (2010) Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development. J Biomed Biotechnol 2010:297505
Hernandes RT, De la Cruz MA, Yamamoto D, Giron JA, Gomes TA (2013) Dissection of the role of pili and type 2 and 3 secretion systems in adherence and biofilm formation of an atypical enteropathogenic Escherichia coli strain. Infect Immun 81(10):3793–3802
Hidas G, Billimek J, Nam A, Soltani T, Kelly MS, Selby B, Dorgalli C, Wehbi E, McAleer I, McLorie G, Greenfield S, Kaplan SH, Khoury AE (2015) Predicting the risk of breakthrough urinary tract infections: primary vesicoureteral reflux. J Urol 194(5):1396–1401
Honish L, Punja N, Nunn S, Nelson D, Hislop N, Gosselin G, Stashko N, Dittrich D (2017) Escherichia coli O157:H7 infections associated with contaminated pork products—Alberta, Canada, July–October 2014. MMWR Morb Mortal Wkly Rep 65(52):1477–1481
Hopkins WJ, Elkahwaji J, Beierle LM, Leverson GE, Uehling DT (2007) Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol 177(4):1349–1353 (quiz 1591)
Huttner A, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Frölich R, Dreyer AM, Martin P, Davies T, Fae K, van den Nieuwenhof I, Thoelen S, de Vallière S, Kuhn A, Bernasconi E, Viereck V, Kavvadias T, Kling K, Ryu G, Hülder T, Gröger S, Scheiner D, Alaimo C, Harbarth S, Poolman J, Fonck VG (2017) Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis 17(5):528–537
Iguchi A, Thomson NR, Ogura Y, Saunders D, Ooka T, Henderson IR, Harris D, Asadulghani M, Kurokawa K, Dean P, Kenny B, Quail MA, Thurston S, Dougan G, Hayashi T, Parkhill J, Frankel G (2009) Complete genome sequence and comparative genome analysis of enteropathogenic Escherichia coli O127:H6 strain E2348/69. J Bacteriol 191(1):347–354
Johnson JR, Miller S, Johnston B, Clabots C, Debroy C (2009) Sharing of Escherichia coli sequence type ST131 and other multidrug-resistant and urovirulent E. coli strains among dogs and cats within a household. J Clin Microbiol 47(11):3721–3725
Kaczmarek A, Budzynska A, Gospodarek E (2014) Detection of K1 antigen of Escherichia coli rods isolated from pregnant women and neonates. Folia Microbiol 59(5):419–422
Kaijser B, Larsson P, Nimmich W, Soderstrom T (1983a) Antibodies to Escherichia coli K and O antigens in protection against acute pyelonephritis. Prog Allergy 33:275–288
Kaijser B, Larsson P, Olling S, Schneerson R (1983b) Protection against acute, ascending pyelonephritis caused by Escherichia coli in rats, using isolated capsular antigen conjugated to bovine serum albumin. Infect Immun 39(1):142–146
Kansal R, Rasko DA, Sahl JW, Munson GP, Roy K, Luo Q, Sheikh A, Kuhne KJ, Fleckenstein JM (2013) Transcriptional modulation of enterotoxigenic Escherichia coli virulence genes in response to epithelial cell interactions. Infect Immun 81(1):259–270
Kaper JB, Nataro JP, Mobley HL (2004) Pathogenic Escherichia coli. Nat Rev Microbiol 2(2):123–140
Keller R, Hilton TD, Rios H, Boedeker EC, Kaper JB (2010) Development of a live oral attaching and effacing Escherichia coli vaccine candidate using Vibrio cholerae CVD 103-HgR as antigen vector. Microb Pathog 48(1):1–8
Kim KS, Kim JY, Jeong IG, Paick JS, Son H, Lim DJ, Shim HB, Park WH, Jung HC, Choo MS (2010) A prospective multi-center trial of Escherichia coli extract for the prophylactic treatment of patients with chronically recurrent cystitis. J Korean Med Sci 25(3):435–439
Kochiashvili D, Khuskivadze A, Kochiashvili G, Koberidze G, Kvakhajelidze V (2014) Role of the bacterial vaccine Solco-Urovac(R) in treatment and prevention of recurrent urinary tract infections of bacterial origin. Georgian Med News 231:11–16
Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, Faruque AS, Zaidi AK, Saha D, Alonso PL, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ochieng JB, Omore R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S, Quadri F, Adegbola RA, Antonio M, Hossain MJ, Akinsola A, Mandomando I, Nhampossa T, Acacio S, Biswas K, O’Reilly CE, Mintz ED, Berkeley LY, Muhsen K, Sommerfelt H, Robins-Browne RM, Levine MM (2013) Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382(9888):209–222
Kumar A, Hays M, Lim F, Foster LJ, Zhou M, Zhu G, Miesner T, Hardwidge PR (2015) Protective enterotoxigenic Escherichia coli antigens in a murine intranasal challenge model. PLoS Negl Trop Dis 9(8):e0003924
Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE, O. Child Health epidemiology reference group of the World Health and Unicef (2013) Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. PLoS One 8(9):e72788
Langermann S, Ballou WR Jr (2001) Vaccination utilizing the FimCH complex as a strategy to prevent Escherichia coli urinary tract infections. J Infect Dis 183(Suppl 1):S84–S86
Langermann S, Mollby R, Burlein JE, Palaszynski SR, Auguste CG, DeFusco A, Strouse R, Schenerman MA, Hultgren SJ, Pinkner JS, Winberg J, Guldevall L, Soderhall M, Ishikawa K, Normark S, Koenig S (2000) Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis 181(2):774–778
Laupland KB, Church DL (2014) Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev 27(4):647–664
Leimbach A, Hacker J, Dobrindt U (2013) E. coli as an all-rounder: the thin line between commensalism and pathogenicity. Curr Top Microbiol Immunol 358:3–32
Leitner DR, Lichtenegger S, Temel P, Zingl FG, Ratzberger D, Roier S, Schild-Prufert K, Feichter S, Reidl J, Schild S (2015) A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles. Front Microbiol 6:823
Lin R, Zhu B, Zhang Y, Bai Y, Zhi F, Long B, Li Y, Wu Y, Wu X, Fan H (2017) Intranasal immunization with novel EspA-Tir-M fusion protein induces protective immunity against enterohemorrhagic Escherichia coli O157:H7 challenge in mice. Microb Pathog 105:19–24
Lipsitch M, Siber GR (2016) How can vaccines contribute to solving the antimicrobial resistance problem? MBio 7(3)
Lloyd JC, Hornik CP, Benjamin DK, Clark RH, Routh JC, Smith PB (2016) Incidence of breakthrough urinary tract infection in hospitalized infants receiving antibiotic prophylaxis. Clin Pediatr (Phila)
Lo Y, Zhang L, Foxman B, Zollner S (2015) Whole-genome sequencing of uropathogenic Escherichia coli reveals long evolutionary history of diversity and virulence. Infect Genet Evol 34:244–250
Logue CM, Doetkott C, Mangiamele P, Wannemuehler YM, Johnson TJ, Tivendale KA, Li G, Sherwood JS, Nolan LK (2012) Genotypic and phenotypic traits that distinguish neonatal meningitis-associated Escherichia coli from fecal E. coli isolates of healthy human hosts. Appl Environ Microbiol 78(16):5824–5830
Lorenzo-Gomez MF, Padilla-Fernandez B, Garcia-Criado FJ, Miron-Canelo JA, Gil-Vicente A, Nieto-Huertos A, Silva-Abuin JM (2013) Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics. Int Urogynecol J 24(1):127–134
Luan J, Zhuang Z, Liu Y, Yun K, Chen M, Wang PG (2010) Expression of EspA in Lactococcus lactis NZ9000 and the detection of its immune effect in vivo and vitro. Immunopharmacol Immunotoxicol 32(1):133–140
Luiz WB, Rodrigues JF, Crabb JH, Savarino SJ, Ferreira LC (2015) Maternal vaccination with a fimbrial tip adhesin and passive protection of neonatal mice against lethal human enterotoxigenic Escherichia coli challenge. Infect Immun 83(12):4555–4564
Lundgren A, Bourgeois L, Carlin N, Clements J, Gustafsson B, Hartford M, Holmgren J, Petzold M, Walker R, Svennerholm AM (2014) Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study. Vaccine 32(52):7077–7084
Luo Q, Kumar P, Vickers TJ, Sheikh A, Lewis WG, Rasko DA, Sistrunk J, Fleckenstein JM (2014) Enterotoxigenic Escherichia coli secretes a highly conserved mucin-degrading metalloprotease to effectively engage intestinal epithelial cells. Infect Immun 82(2):509–521
Magasi P, Panovics J, Illes A, Nagy M (1994) Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. Eur Urol 26(2):137–140
Mathers AJ, Peirano G, Pitout JD (2015) Escherichia coli ST131: the quintessential example of an international multiresistant high-risk clone. Adv Appl Microbiol 90:109–154
Matthews L, Reeve R, Gally DL, Low JC, Woolhouse ME, McAteer SP, Locking ME, Chase-Topping ME, Haydon DT, Allison LJ, Hanson MF, Gunn GJ, Reid SW (2013) Predicting the public health benefit of vaccinating cattle against Escherichia coli O157. Proc Natl Acad Sci U S A 110(40):16265–16270
McNeilly TN, Mitchell MC, Corbishley A, Nath M, Simmonds H, McAteer SP, Mahajan A, Low JC, Smith DG, Huntley JF, Gally DL (2015) Optimizing the protection of cattle against Escherichia coli O157:H7 colonization through immunization with different combinations of H7 Flagellin, Tir, Intimin-531 or EspA. PLoS ONE 10(5):e0128391
Mellata M, Mitchell NM, Schodel F, Curtiss R 3rd, Pier GB (2016) Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis. Vaccine 34(5):656–662
Micenkova L, Bosak J, Vrba M, Sevcikova A, Smajs D (2016) Human extraintestinal pathogenic Escherichia coli strains differ in prevalence of virulence factors, phylogroups, and bacteriocin determinants. BMC Microbiol 16:218
Mobley HL, Alteri CJ (2015) Development of a vaccine against Escherichia coli urinary tract infections. Pathogens 5(1)
Mohawk KL, Melton-Celsa AR, Robinson CM, O’Brien AD (2010) Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7. Vaccine 28(30):4777–4785
Moriel DG, Bertoldi I, Spagnuolo A, Marchi S, Rosini R, Nesta B, Pastorello I, Corea VA, Torricelli G, Cartocci E, Savino S, Scarselli M, Dobrindt U, Hacker J, Tettelin H, Tallon LJ, Sullivan S, Wieler LH, Ewers C, Pickard D, Dougan G, Fontana MR, Rappuoli R, Pizza M, Serino L (2010) Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A 107(20):9072–9077
Moriel DG, Rosini R, Seib KL, Serino L, Pizza M, Rappuoli R (2012) Escherichia coli: great diversity around a common core. MBio 3(3)
Nesta B, Spraggon G, Alteri C, Moriel DG, Rosini R, Veggi D, Smith S, Bertoldi I, Pastorello I, Ferlenghi I, Fontana MR, Frankel G, Mobley HL, Rappuoli R, Pizza M, Serino L, Soriani M (2012) FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio 3(2)
Nesta B, Valeri M, Spagnuolo A, Rosini R, Mora M, Donato P, Alteri CJ, Del Vecchio M, Buccato S, Pezzicoli A, Bertoldi I, Buzzigoli L, Tuscano G, Falduto M, Rippa V, Ashhab Y, Bensi G, Fontana MR, Seib KL, Mobley HL, Pizza M, Soriani M, Serino L (2014) SslE elicits functional antibodies that impair in vitro mucinase activity and in vivo colonization by both intestinal and extraintestinal Escherichia coli strains. PLoS Pathog 10(5):e1004124
Nguyen QN, Himes JE, Martinez DR, Permar SR (2016) The impact of the Gut Microbiota on humoral immunity to pathogens and vaccination in early infancy. PLoS Pathog 12(12):e1005997
Nicolas-Chanoine MH, Bertrand X, Madec JY (2014) Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 27(3):543–574
Nordstrom L, Liu CM, Price LB (2013) Foodborne urinary tract infections: a new paradigm for antimicrobial-resistant foodborne illness. Front Microbiol 4:29
Norman JM, Handley SA, Virgin HW (2014) Kingdom-agnostic metagenomics and the importance of complete characterization of enteric microbial communities. Gastroenterology 146(6):1459–1469
Norton EB, Lawson LB, Freytag LC, Clements JD (2011) Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol 18(4):546–551
Norton EB, Lawson LB, Mahdi Z, Freytag LC, Clements JD (2012) The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infect Immun 80(7):2426–2435
Norton EB, Branco LM, Clements JD (2015) Evaluating the A-subunit of the Heat-Labile Toxin (LT) as an immunogen and a protective antigen against enterotoxigenic Escherichia coli (ETEC). PLoS ONE 10(8):e0136302
O’Hanley P, Lalonde G, Ji G (1991) Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis. Infect Immun 59(3):1153–1161
Ohland CL, Macnaughton WK (2010) Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 298(6):G807–G819
Oliveira AF, Cardoso SA, Almeida FB, de Oliveira LL, Pitondo-Silva A, Soares SG, Hanna ES (2012) Oral immunization with attenuated Salmonella vaccine expressing Escherichia coli O157:H7 intimin gamma triggers both systemic and mucosal humoral immunity in mice. Microbiol Immunol 56(8):513–522
Orskov F, Orskov I (1992) Escherichia coli serotyping and disease in man and animals. Can J Microbiol 38(7):699–704
Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, Galeotti CL, Luzzi E, Manetti R, Marchetti E, Mora M, Nuti S, Ratti G, Santini L, Savino S, Scarselli M, Storni E, Zuo P, Broeker M, Hundt E, Knapp B, Blair E, Mason T, Tettelin H, Hood DW, Jeffries AC, Saunders NJ, Granoff DM, Venter JC, Moxon ER, Grandi G, Rappuoli R (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287(5459):1816–1820
Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, Mills KH, Rappuoli R, Del Giudice G (2001) Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19(17–19):2534–2541
Poolman JT, Wacker M (2016) Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field. J Infect Dis 213(1):6–13
Punina NV, Makridakis NM, Remnev MA, Topunov AF (2015) Whole-genome sequencing targets drug-resistant bacterial infections. Hum Genomics 9:19
Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Meta HITC, Bork P, Ehrlich SD, Wang J (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464(7285):59–65
Rabinovitz BC, Gerhardt E, Tironi Farinati C, Abdala A, Galarza R, Vilte DA, Ibarra C, Cataldi A, Mercado EC (2012) Vaccination of pregnant cows with EspA, EspB, gamma-intimin, and Shiga toxin 2 proteins from Escherichia coli O157:H7 induces high levels of specific colostral antibodies that are transferred to newborn calves. J Dairy Sci 95(6):3318–3326
Ranallo RT, Fonseka CP, Cassels F, Srinivasan J, Venkatesan MM (2005) Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli. Infect Immun 73(1):258–267
Rappuoli R (2001a) Conjugates and reverse vaccinology to eliminate bacterial meningitis. Vaccine 19(17–19):2319–2322
Rappuoli R (2001b) Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19(17–19):2688–2691
Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, Scheutz F, Paxinos EE, Sebra R, Chin CS, Iliopoulos D, Klammer A, Peluso P, Lee L, Kislyuk AO, Bullard J, Kasarskis A, Wang S, Eid J, Rank D, Redman JC, Steyert SR, Frimodt-Moller J, Struve C, Petersen AM, Krogfelt KA, Nataro JP, Schadt EE, Waldor MK (2011) Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 365(8):709–717
Riddle MS, Savarino SJ (2014) Moving beyond a heat-labile enterotoxin-based vaccine against enterotoxigenic Escherichia coli. Lancet Infect Dis 14(3):174–175
Robins-Browne RM, Holt KE, Ingle DJ, Hocking DM, Yang J, Tauschek M (2016) Are Escherichia coli pathotypes still relevant in the era of whole-genome sequencing? Front Cell Infect Microbiol 6:141
Rojas RL, Gomes PA, Bentancor LV, Sbrogio-Almeida ME, Costa SO, Massis LM, Ferreira RC, Palermo MS, Ferreira LC (2010) Salmonella enterica serovar Typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli. Clin Vaccine Immunol 17(4):529–536
Roubaud Baudron C, Panhard X, Clermont O, Mentre F, Fantin B, Denamur E, Lefort A, C. Group (2014) Escherichia coli bacteraemia in adults: age-related differences in clinical and bacteriological characteristics, and outcome. Epidemiol Infect 142(12):2672–2683
Roy K, Hamilton DJ, Fleckenstein JM (2012) Cooperative role of antibodies against heat-labile toxin and the EtpA Adhesin in preventing toxin delivery and intestinal colonization by enterotoxigenic Escherichia coli. Clin Vaccine Immunol 19(10):1603–1608
Roy K, Hilliard GM, Hamilton DJ, Luo J, Ostmann MM, Fleckenstein JM (2009) Enterotoxigenic Escherichia coli EtpA mediates adhesion between flagella and host cells. Nature 457(7229):594–598
Ruan X, Robertson DC, Nataro JP, Clements JD, Zhang W, S.T.T.V.C. Group (2014). Characterization of heat-stable (STa) toxoids of enterotoxigenic Escherichia coli fused to double mutant heat-labile toxin peptide in inducing neutralizing anti-STa antibodies. Infect Immun 82(5):1823–1832
Ruan X, Sack DA, Zhang W (2015) Genetic fusions of a CFA/I/II/IV MEFA (multiepitope fusion antigen) and a toxoid fusion of heat-stable toxin (STa) and heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC) retain broad anti-CFA and antitoxin antigenicity. PLoS ONE 10(3):e0121623
Russo TA, Johnson JR (2006) Extraintestinal isolates of Escherichia coli: identification and prospects for vaccine development. Expert Rev Vaccines 5(1):45–54
Sack DA, Shimko J, Torres O, Bourgeois AL, Francia DS, Gustafsson B, Karnell A, Nyquist I, Svennerholm AM (2007) Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. coli diarrhoea of travellers to Guatemala and Mexico. Vaccine 25(22):4392–4400
Schmidhammer S, Ramoner R, Holtl L, Bartsch G, Thurnher M, Zelle-Rieser C (2002) An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology 60(3):521–526
Sharapov UM, Wendel AM, Davis JP, Keene WE, Farrar J, Sodha S, Hyytia-Trees E, Leeper M, Gerner-Smidt P, Griffin PM, Braden C, Outbreak Investigation T (2016) Multistate Outbreak of Escherichia coli O157:H7 infections associated with consumption of fresh Spinach: United States, 2006. J Food Prot 79(12):2024–2030
Sheikh A, Luo Q, Roy K, Shabaan S, Kumar P, Qadri F, Fleckenstein JM (2014) Contribution of the highly conserved EaeH surface protein to enterotoxigenic Escherichia coli pathogenesis. Infect Immun 82(9):3657–3666
Sincock SA, Hall ER, Woods CM, O’Dowd A, Poole ST, McVeigh AL, Nunez G, Espinoza N, Miller M, Savarino SJ (2016) Immunogenicity of a prototype enterotoxigenic Escherichia coli adhesin vaccine in mice and nonhuman primates. Vaccine 34(2):284–291
Sivick KE, Mobley HL (2009) An “omics” approach to uropathogenic Escherichia coli vaccinology. Trends Microbiol 17(10):431–432
Srivastava A, Gowda DV, Madhunapantula V, Siddaramaiah S (2016) Development and efficacy assessment of an enteric coated porous tablet loaded with F4 fimbriae for oral vaccination of piglets against F4+ Escherichia coli infections. Curr Drug Deliv 13(1):121–130
Takeyama N, Yuki Y, Tokuhara D, Oroku K, Mejima M, Kurokawa S, Kuroda M, Kodama T, Nagai S, Ueda S, Kiyono H (2015) Oral rice-based vaccine induces passive and active immunity against enterotoxigenic E. coli-mediated diarrhea in pigs. Vaccine 33(39):5204–5211
Tammen H (1990) Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group. Br J Urol 65(1):6–9
Taxt A, Aasland R, Sommerfelt H, Nataro J, Puntervoll P (2010) Heat-stable enterotoxin of enterotoxigenic Escherichia coli as a vaccine target. Infect Immun 78(5):1824–1831
Uehling DT, Hopkins WJ, Beierle LM, Kryger JV, Heisey DM (2001) Vaginal mucosal immunization for recurrent urinary tract infection: extended phase II clinical trial. J Infect Dis 183(Suppl 1):S81–S83
Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE (2003) Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol 170(3):867–869
Uehling DT, Wolf L (1969) Enhancement of the bladder defense mechanism by immunization. Invest Urol 6(5):520–526
Valeri M, Rossi Paccani S, Kasendra M, Nesta B, Serino L, Pizza M, Soriani M (2015) Pathogenic E. coli exploits SslE mucinase activity to translocate through the mucosal barrier and get access to host cells. PLoS ONE 10(3):e0117486
Vigil PD, Alteri CJ, Mobley HL (2011) Identification of in vivo-induced antigens including an RTX family exoprotein required for uropathogenic Escherichia coli virulence. Infect Immun 79(6):2335–2344
Wagenlehner FM, Ballarini S, Pilatz A, Weidner W, Lehr L, Naber KG (2015) A randomized, double-blind, parallel-group, multicenter clinical study of Escherichia coli-lyophilized lysate for the prophylaxis of recurrent uncomplicated urinary tract infections. Urol Int 95(2):167–176
Walker WA (2013) Initial intestinal colonization in the human infant and immune homeostasis. Ann Nutr Metab 63(Suppl 2):8–15
Whitfield C (2006) Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu Rev Biochem 75:39–68
Wieser A, Romann E, Magistro G, Hoffmann C, Norenberg D, Weinert K, Schubert S (2010) A multiepitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice. Infect Immun 78(8):3432–3442
Wu HJ, Wu E (2012) The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes 3(1):4–14
Yang J, Baldi DL, Tauschek M, Strugnell RA, Robins-Browne RM (2007) Transcriptional regulation of the yghJ-pppA-yghG-gspCDEFGHIJKLM cluster, encoding the type II secretion pathway in enterotoxigenic Escherichia coli. J Bacteriol 189(1):142–150
Zhang W, Sack DA (2015) Current Progress in developing subunit vaccines against enterotoxigenic Escherichia coli-associated diarrhea. Clin Vaccine Immunol 22(9):983–991
Zhang XH, He KW, Zhang SX, Lu WC, Zhao PD, Luan XT, Ye Q, Wen LB, Li B, Guo RL, Wang XM, Lv LX, Zhou JM, Yu ZY, Mao AH (2011) Subcutaneous and intranasal immunization with Stx2B-Tir-Stx1B-Zot reduces colonization and shedding of Escherichia coli O157:H7 in mice. Vaccine 29(22):3923–3929
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Nesta, B., Pizza, M. (2018). Vaccines Against Escherichia coli. In: Frankel, G., Ron, E. (eds) Escherichia coli, a Versatile Pathogen. Current Topics in Microbiology and Immunology, vol 416. Springer, Cham. https://doi.org/10.1007/82_2018_111
Download citation
DOI: https://doi.org/10.1007/82_2018_111
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99663-9
Online ISBN: 978-3-319-99664-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)